Universal Cells
Rachel Knopp is a Scientist at Universal Cells, having previously held positions as a Postdoctoral Scholar Fellow at the University of Washington and a Postdoctoral Researcher at the Seattle Institute for Biomedical and Clinical Research. They received their Ph.D. in Medicinal and Pharmaceutical Chemistry from the University of Illinois at Chicago after completing a Bachelor of Arts in Biochemistry from Willamette University. During their career, Rachel has also worked as a Graduate Teaching Assistant at the University of Illinois at Chicago and completed an internship at Eli Lilly and Company's Neurodegeneration Clinical Team.
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.